56.3 F
New York
Tuesday, May 17, 2022

Sage Therapeutics [NASDAQ: SAGE] Names Barry Greene As The New CEO

Must read

Sage Therapeutics [NASDAQ: SAGE] reports that the company has appointed Barry Greene as its new CEO. Moreover, Barry holds global expertise and success in R&D and commercialization. He as part of the SAGE will aid the company in enhancing its mission. The mission to deliver transformational healthcare drugs for people suffering from brain health disorders

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Moreover, The decision to appoint barry as the CEO was to enhance the growth of the company in the brain health space. Berry recently was the president of Alnylam Pharmaceuticals and provide his services to that company from 2007 to 2020.

Barry Greene stated “ The company is taking a big step trying to change lives of people suffering from brain disorders. I anticipate working with an enthusiastic crew as we continue to grow the companies multi-franchise strategy. Furthermore, We will work together to deliver the mission of the company to bring a positive influence on the lives of people with brain disorders”

More articles

Latest article